Surrogate Markers Core

$419,720P30FY2013MHNIH

Johns Hopkins University, Baltimore MD

Investigators

Linked publications, trials & patents

Paper 39723835 Paper 39615660 Paper 39521602 Paper 39255061 Paper 39253970 Paper 39145637 Paper 38985447 Paper 38869661 Paper 38472641 Paper 38411600 Paper 38329107 Paper 38237559 Paper 38017485 Paper 37773048 Paper 37546800 Paper 37536209 Paper 37502930 Paper 37406093 Paper 37406092 Paper 37034720 Paper 36973419 Paper 36961349 Paper 36930636 Paper 36656093 Paper 36603748 Paper 36297501 Paper 36162063 Paper 36044606 Paper 35980773 Paper 35746785 Paper 35734753 Paper 35462006 Paper 35357949 Paper 35178611 Paper 34400301 Paper 34333739 Paper 34074816 Paper 34033600 Paper 33947785 Paper 33914710 Paper 33811859 Paper 33798648 Paper 33551684 Paper 33438895 Paper 33423010 Paper 33408815 Paper 33395289 Paper 33394812 Paper 33359628 Paper 33069080 Paper 33009012 Paper 32880873 Paper 32675407 Paper 32638219 Paper 32209807 Paper 32108673 Paper 32032278 Paper 31930991 Paper 31914004 Paper 31726921 Paper 31721082 Paper 31634200 Paper 31373216 Paper 31273753 Paper 31218522 Paper 31209775 Paper 31201294 Paper 31165368 Paper 31107302 Paper 30946151 Paper 30893126 Paper 30883361 Paper 30865184 Paper 30862949 Paper 30787163 Paper 30671779 Paper 30671778 Paper 30649046 Paper 30607892 Paper 30552009 Paper 30535238 Paper 30531925 Paper 30181331 Paper 30127344 Paper 30010121 Paper 30008143 Paper 29969024 Paper 29746297 Paper 29507357 Paper 29449278 Paper 29379089 Paper 29257872 Paper 29147885 Paper 29063516 Paper 28956014 Paper 28875261 Paper 28800041 Paper 28763226 Trial NCT01354314 Patent 9289412

Abstract

SURROGATE MARKERS CORE PROJECT SUMMARY (See instructions): Neurocognitive impairment in HIV-infected individuals remains a significant problem despite antiretroviral therapy. There is a critical need for surrogate markers that can be used to predict cognitive impairment and to monitor the effects of antiretroviral, or neuroprotective therapy in HIV-infected individuals. The primary goals of the Surrogate Marker / Pharmacokinetic Core will be to: 1) Assist in the development and monitoring of surrogate markers for HIV-associated neurocognitive disorders (HAND). 2) To provide mentorship and consultation for Neuro-AIDS researchers in the development of clinically useful surrogate markers for HAND and to validate these as predictive and associative markers for cognitive impairment and as surrogate markers for therapeutic effectiveness. An additional task ofthe core will be to assist in the development of small molecule therapeufics by providing consultation on pharamcokinetic/pharmacodynamic considerations for drug development, and conducting pharmacokinetic and analysis of potential drugs and drug metabolites.

View original record on NIH RePORTER →